Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Unicycive Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
UNCY
Nasdaq
8731
https://unicycive.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Unicycive Therapeutics Inc
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
- Apr 10th, 2024 11:03 am
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
- Mar 28th, 2024 8:15 pm
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
- Mar 25th, 2024 11:03 am
Unicycive Announces $50 Million Private Placement
- Mar 14th, 2024 11:03 am
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
- Mar 13th, 2024 11:03 am
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
- Mar 7th, 2024 9:12 pm
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
- Mar 4th, 2024 12:03 pm
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
- Feb 14th, 2024 12:03 pm
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
- Feb 6th, 2024 11:13 am
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
- Jan 29th, 2024 12:03 pm
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
- Jan 24th, 2024 2:39 pm
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
- Jan 23rd, 2024 12:03 pm
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
- Dec 18th, 2023 12:03 pm
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
- Nov 29th, 2023 12:03 pm
Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)
- Nov 17th, 2023 10:12 am
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 9:15 pm
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
- Oct 23rd, 2023 11:03 am
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
- Sep 6th, 2023 11:03 am
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
- Aug 29th, 2023 11:03 am
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
- Aug 17th, 2023 10:21 am
Scroll